



Micromedic Reports Successful Interim Results from Bladder Cancer Clinical Study

Micromedic is proceeding with the development of its CellDetect® technology for monitoring the recurrence of bladder cancer

TEL AVIV (July 1, 2014) - Micromedic Technologies (TASE: MCTC), The cancer diagnostic cluster company of BioLight, achieved successful interim results in a blinded bladder cancer clinical trial with its CellDetect® technology. Micromedic is continuing the trial with the goal of developing a kit for monitoring the recurrence of bladder cancer. This study is being conducted at seven medical centers and is expected to be completed in the fourth quarter of 2014.

The interim report indicates sensitivity of the CellDetect® technology method of 88% and specificity of 68%. The results of the test using the CellDetect® technology were compared with results from biopsy or from cystoscopy in cases where biopsies were not taken. The interim results are based on 65 urine samples, of which 25 samples were from bladder cancer patients and 40 were from healthy individuals with a history of bladder cancer.

The test's high sensitivity was repeated among subjects identified as high-grade (advanced) cancer patients as well as among subjects identified as low-grade (early stage) cancer patients.

Steven Eitan, Micromedic's chief executive officer, said, "These results are very encouraging and are likely to advance the company towards commercializing the second kit using the proprietary CellDetect® technology. Several non-invasive tests in the market for monitoring bladder cancer are characterized with low sensitivity and precision and few are costly, the invasive test (Cystoscopy), involves discomfort, and is very expensive. As such, should the interim results be confirmed by final study results, we believe that a test kit incorporating this technology will be positioned with advantages for commercial success".

About Bladder Cancer

Bladder cancer is the fourth most prevalent cancer among males in the U.S. and the seventh most prevalent among males worldwide, with nearly 430,000 new case of the disease diagnosed globally in 2012. The rate of recurrence is the highest of all cancers and ranges from 50% to 80%. According to U.S. clinical guidelines, patients with a history of urinary bladder cancer are required to undergo three to four tests per year to monitor disease recurrence in the first two years immediately following treatment, and one test annually in the years that follow. Because of high recurrence rates, the cost of diagnosing and treating bladder cancer is among the highest of all cancers.

About CellDetect®

The CellDetect® technology uses proprietary staining to help distinguish cancerous cells from healthy cells. This technology facilitates the performance of tests for detecting cancer by diagnosing the cancerous cells and also following the recurrence of the disease in patients after treatment. Micromedic is using CellDetect® to detect and identify cervical cancer and



monitor the recurrence of bladder cancer. The cervical cancer detection screening diagnostic test kit is in the initial commercial stage and Micromedic is conducting a clinical trial to prove its ability to monitor bladder cancer recurrence. Micromedic believes that the underlying technology may be adapted for other types of cancer as well.

About Micromedic

Micromedic (TASE: MCTC) engages in the investment, management and promotion of products for the early detection of cancers and to match personal treatment to the patient. Micromedic's investment model is designed to create synergies between its technologies, enabling tackling the problem from different viewpoints, expanding exposure to new ideas and approaches, exploiting economies of scale, reducing time to market and increasing shareholder value. Micromedic has extensive collaborations with commercial companies and research institutions worldwide.

For further information please visit www.m-medic.com